Intercept Pharmaceuticals Just Filed Its Quarterly Report: 15.   Net Loss Per ...

15.   Net Loss Per Share

Basic loss per share is computed by dividing net loss attributable to common stockholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. For the three and six-month periods ended June 30, 2021 and 2020, as the Company was in a net loss position, the diluted loss per share computations for such periods did not assume the conversion of the Convertible Notes, exercise of stock options or vesting of RSUs or PRSUs as they would have had an anti-dilutive effect on loss per share.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding for the three and six-month periods ended June 30, 2021 and 2020, as the inclusion thereof would have been anti-dilutive:

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2021

    

2020

2021

    

2020

    

(in thousands)

(in thousands)

Shares issuable upon conversion of Convertible Notes

4,435

4,435

4,435

4,435

Options

 

2,729

 

2,422

2,727

 

2,492

 

Unvested restricted stock units

 

1,211

 

849

1,220

 

893

 

Total

 

8,375

 

7,706

8,382

 

7,820

 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Business Update - Aug. 3, 2022
Intercept Pharmaceuticals Just Filed Its Quarterly Report: 14.   Net Loss Per ... - Aug. 3, 2022
Intercept Pharmaceuticals's General Counsel just disposed of 771 shares - Aug. 3, 2022
On July - July 26, 2022
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 436 shares - July 13, 2022

Auto Refresh

Feedback